What are the clinical results of the mRNA vaccine to prevent influenza Moderna?

On December 10, 2021, Moderna announced that its Phase 1 clinical trial of the influenza vaccine mRNA-1010 has obtained positive interim data

The epidemic of seasonal flu causes respiratory diseases and places a huge burden on the healthcare system

However, the current influenza vaccines are only about 40-60% effective, and their formulations were decided 6-9 months before the planned use of the vaccine

This phase 1 clinical trial evaluated the effects of 3 doses of mRNA-1010 (50 µg, 100 µg, and 200 µg) in a cohort of young adults (18-49 years) and elderly (over 50 years)

▲The immunogenicity data of mRNA-1010 in young adults (picture source: Moderna official website)

In the elderly group, compared with baseline, the increase in antibody GMT was 6 times (H1N1), 6 times (H3N2), 3 times (Yamagata), and 2 times (Victoria)

In terms of safety, no serious safety signals were observed

Mr.

Reference materials:

[1] Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update.